These are top 10 stocks traded on the Robinhood UK platform in July
On Thursday, Stifel analysts maintained their Hold rating on The Beauty Health Company (NASDAQ:SKIN) with a steady price target of $2.00. The company’s fourth-quarter results for the fiscal year 2024 showed robust performance, with revenue exceeding expectations and EBITDA surpassing forecasts significantly, thanks in part to impressive gross margins of 50.5%. According to InvestingPro data, the company’s current market capitalization stands at $176 million, with the stock showing a significant 12.7% return over the last week despite broader market challenges. This marks the second consecutive quarter where the company has delivered on both revenue and EBITDA, signaling growing momentum under the new management team.
The new management has been actively making strategic decisions, such as transitioning to a distributor model in China, consolidating manufacturing operations, and implementing organizational changes. These moves are part of the company’s efforts to streamline operations and improve efficiency. InvestingPro analysis indicates the company maintains strong liquidity with a current ratio of 6.56, though it faces some challenges with debt management. For detailed insights into SKIN’s financial health and future prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
Despite these positive developments, The Beauty Health Company’s 2025 revenue guidance, with a midpoint of $285 million, fell short of analysts’ expectations, which were set at $338 million and consensus forecasts of $333 million. The shortfall in projected sales could be partially attributed to the company’s shift to a distribution model in China, which is expected to impact sales by $10-15 million. InvestingPro data reveals additional challenges, with analysts anticipating a sales decline in the current year and revising earnings expectations downward. The platform offers 12 additional exclusive ProTips that provide deeper insights into SKIN’s investment potential. Additionally, the guidance for the first quarter of 2025 suggests a stronger sales increase in the latter part of the year, which is necessary for the company to achieve its EBITDA targets for the year.
The guidance provided by the company’s management indicates a year-over-year increase of $5 million in EBITDA, despite an anticipated $50 million decline in revenue. This implies a significant EBITDA margin expansion of 250 basis points year-over-year, which would need to be realized amidst decreasing sales. Stifel analysts are looking for greater confidence in the company’s ability to ramp up sales in line with the management’s guidance, which is critical for reaching the projected EBITDA figures. Based on InvestingPro’s Fair Value analysis, SKIN currently appears to be trading near its Fair Value, with the platform’s Financial Health Score indicating "FAIR" overall conditions.
In other recent news, The Beauty Health Company reported its fourth-quarter earnings for 2024, which exceeded analyst expectations. The company posted an earnings per share (EPS) of -$0.08, surpassing the forecasted -$0.11, and achieved a revenue of $83.5 million, outperforming the expected $77.39 million. Despite these positive financial results, Canaccord Genuity revised its price target for the company’s shares, lowering it to $1.50 while maintaining a Hold rating. The decision followed a 13.8% decline in fourth-quarter sales, although this was better than anticipated declines.
The Beauty Health Company’s adjusted EBITDA reached $9.0 million, surpassing estimates that predicted a loss, and the company ended the quarter with a strong cash position of $370 million. However, challenges remain, particularly with new machine placements, which are impacted by broader macroeconomic conditions and high-interest rates. The company has responded by transitioning its China business to a distributor model and offering lower-cost and refurbished machines. Looking ahead, Beauty Health Co projects 2025 sales between $270 million and $300 million, with adjusted EBITDA expected to range from $10 million to $25 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.